TISIDB

Summary
Symbol	EEF1A2
Name	eukaryotic translation elongation factor 1 alpha 2
Aliases	STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location	20q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF00009 Elongation factor Tu GTP binding domain PF03144 Elongation factor Tu domain 2 PF03143 Elongation factor Tu C-terminal domain
Function	This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis.

> Gene Ontology [ TOP ]
Biological Process	GO:0006414 translational elongation GO:0006914 autophagy GO:0010035 response to inorganic substance GO:0010506 regulation of autophagy GO:0019216 regulation of lipid metabolic process GO:0033674 positive regulation of kinase activity GO:0043550 regulation of lipid kinase activity GO:0045834 positive regulation of lipid metabolic process GO:0051602 response to electrical stimulus GO:0061684 chaperone-mediated autophagy GO:0090218 positive regulation of lipid kinase activity GO:1904714 regulation of chaperone-mediated autophagy
Molecular Function	GO:0003746 translation elongation factor activity GO:0003924 GTPase activity GO:0005525 GTP binding GO:0008135 translation factor activity, RNA binding GO:0019001 guanyl nucleotide binding GO:0032561 guanyl ribonucleotide binding
Cellular Component	GO:0005765 lysosomal membrane GO:0005853 eukaryotic translation elongation factor 1 complex GO:0043025 neuronal cell body GO:0043209 myelin sheath GO:0044297 cell body GO:0098552 side of membrane GO:0098562 cytoplasmic side of membrane GO:0098574 cytoplasmic side of lysosomal membrane GO:0098852 lytic vacuole membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03013 RNA transport
Reactome	R-HSA-156842: Eukaryotic Translation Elongation R-HSA-74160: Gene Expression R-HSA-392499: Metabolism of proteins R-HSA-72766: Translation

Summary
Symbol	EEF1A2
Name	eukaryotic translation elongation factor 1 alpha 2
Aliases	STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location	20q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between EEF1A2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between EEF1A2 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
24068664	Bladder Carcinoma	Essential for immunotherapy	In vitro studies were conducted to determine the interaction of BCG with high-grade bladder cancer cell line overexpressing sTn. sTn or s6T expression was associated with BCG response (P=0.024; P<0.0001) and with increased recurrence-free survival (P=0.001). Multivariate analyses showed that sTn and/or s6T were independent predictive markers of recurrence after BCG immunotherapy (HR=0.296; (0.148-0.594); P=0.001). Our data strongly suggest that BCG immunotherapy is efficient against sTn- and s6T-positive tumours.

Summary
Symbol	EEF1A2
Name	eukaryotic translation elongation factor 1 alpha 2
Aliases	STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location	20q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of EEF1A2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	EEF1A2
Name	eukaryotic translation elongation factor 1 alpha 2
Aliases	STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location	20q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of EEF1A2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.123	0.904
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.324	0.859
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.025	0.987
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.76	0.376
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	1.517	0.356
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.201	0.916
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.205	0.831
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.01	0.994
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.138	0.922
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.157	0.928
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-1.768	0.436
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.686	0.0843

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of EEF1A2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	0	25	0.222
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	EEF1A2
Name	eukaryotic translation elongation factor 1 alpha 2
Aliases	STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location	20q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EEF1A2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	EEF1A2
Name	eukaryotic translation elongation factor 1 alpha 2
Aliases	STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location	20q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EEF1A2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EEF1A2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	EEF1A2
Name	eukaryotic translation elongation factor 1 alpha 2
Aliases	STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location	20q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EEF1A2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	EEF1A2
Name	eukaryotic translation elongation factor 1 alpha 2
Aliases	STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location	20q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of EEF1A2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	EEF1A2
Name	eukaryotic translation elongation factor 1 alpha 2
Aliases	STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location	20q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between EEF1A2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	EEF1A2
Name	eukaryotic translation elongation factor 1 alpha 2
Aliases	STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location	20q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting EEF1A2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse EEF1A2